Cantor Fitzgerald Reiterates Overweight on Denali Therapeutics, Maintains $85 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Denali Therapeutics (NASDAQ:DNLI) and maintained a price target of $85.
August 31, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Denali Therapeutics and maintained a price target of $85.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Denali Therapeutics. The maintained price target of $85 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100